Vaxart Inc (VXRT)

1.110
+0.030(+2.78%)
After Hours
1.070
-0.040(-3.604%)
- Real-time Data
  • Volume:
    1,392,462
  • Day's Range:
    1.060 - 1.130
  • 52 wk Range:
    0.732 - 5.430

VXRT Overview

Prev. Close
1.08
Day's Range
1.06-1.13
Revenue
85K
Open
1.07
52 wk Range
0.732-5.43
EPS
-0.829
Volume
1,392,462
Market Cap
145.69M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
3,389,556
P/E Ratio
-1.34
Beta
-
1-Year Change
-74.19%
Shares Outstanding
131,249,086
Next Earnings Date
23 Feb 2023
What is your sentiment on Vaxart?
or
Market is currently closed. Voting is open during market hours.

Vaxart Inc News

Vaxart Inc Company Profile

Vaxart Inc Company Profile

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The Company is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyStrong BuyBuyStrong Sell
Technical IndicatorsStrong SellStrong BuyBuyNeutralStrong Sell
SummarySellStrong BuyStrong BuyNeutralStrong Sell
  • Ready to flight today?
    0
    • Kindred Biosciences [KIN] - Last Close: $6.34 Kindred Biosciences just agreed to be acquired in a multimillion-dollar deal.Elanco Animal Health (ELAN) will buy all outstanding shares of KIN for $9.25 per share in a deal worth $440 million. Elanco says it will fund the acquisition with pre-payable debt, and the deal is expected to add roughly $100 million to Elanco's innovation revenue expectations by 2025. Closing is slotted for sometime in the third quarter. KIN is up 45.1% on active trading volume on the buyout news.
      0
      • sorry l am confused what has all this got to do with Vaxart?
        0
      • James OlojoKindred has a contract to manufacture Vaxart vaccines
        0
    • Who is ready to flight wihy Vaxart!💪🏻
      0
      • Galin BoshnakovVaxart is a very promising action, its VAAST patent is the only one in the world and will revolutionize the market, my goal is once again the historical highs and if the manipulation continues it will touch 30-32 $
        0
      • What’s your avg. cost
        0
      • 0
    • Hopefully this drops below 7$, then I can buy.
      1
      • hello guys is it a good time to buy ?
        1
        • buy
          0
      • hello guys is it a good time to buy ?
        1
        • hello guys is it a good time to buy ?
          0
          • Likely will SKYROCKET monday with good news from update on covid oral vaccinw
            0
            • what's happening with vaxart???
              0
              • up or down
                0